Form 4: Immunovant CTO Sells Shares for Tax Obligations

Immunovant's Chief Technology Officer, Jay S Stout, sold 1,977 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• Jay S Stout, Immunovant's Chief Technology Officer, reported a transaction on January 21, 2026.
• He sold 1,977 shares of Immunovant Common Stock at a price of $26.03 per share.
• The sale was a "sell to cover" transaction, mandated by Immunovant, Inc., to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs).
• Specifically, 6,250 RSUs, which were part of a 100,000 RSU grant on April 17, 2023, vested on January 17, 2026.
• Following this transaction, Jay S Stout beneficially owns 197,634 shares of Immunovant Common Stock.

Sentiment

Score: 5

Explanation: The filing reports a routine, non-discretionary 'sell to cover' transaction by an executive to satisfy tax obligations upon RSU vesting, which is a neutral event with no direct positive or negative implications for the company's operational or financial performance.

Management Comments

• The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs.
• The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

Industry Context

This is a routine insider transaction related to executive compensation and does not provide specific insights into broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: Minimal impact as the transaction is a routine, non-discretionary sale for tax purposes and represents a small fraction of the company's outstanding shares.

Key Dates

Recommendation

The reported transaction is a standard 'sell to cover' by an executive to meet tax obligations upon RSU vesting, not a discretionary sale. This type of transaction is a routine part of executive compensation and does not reflect a change in the company's fundamentals or the executive's confidence in the company. Therefore, it does not warrant a change in investment recommendation.

Keywords

Immunovant, IMVT, Form 4, Insider Transaction, Stock Sale, RSU Vesting, Tax Withholding, Chief Technology Officer, Jay S Stout